GlassScriptPhysician profile
Abigail Randall
NPI 1104443308
$1,333.33
in general payments reported to CMS, 2019-2025
19 companies · $934 in 2025
The $934 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.39 · 2023: $135 · 2024: $246 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $192.76 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $190.45 | 2024-2025 | Ingrezza |
| Biogen, INC. | $141.56 | 2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.47 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $119.41 | 2024-2025 | Rexulti |
| Lundbeck LLC | $107.00 | 2025 | Rexulti |
| Atricure, INC. | $90.87 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.67 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $72.69 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $35.18 | 2025 | Xelstrym |
| Alkermes, INC. | $28.52 | 2023-2025 | Lybalvi, Aristada |
| Genentech USA, INC. | $23.15 | 2023 | Tecentriq |
| Cerus Corporation | $22.45 | 2023 | Intercept Blood System For Platelets |
| Collegium Pharmaceutical, INC. | $19.26 | 2025 | Jornay Pm |
| Werfen USA LLC | $18.39 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.68 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $16.81 | 2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $16.67 | 2025 | Qelbree |
| Alpha Orthopedic Systems | $14.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.